Roble, Belko & Company, Inc Biogen Inc. Transaction History
Roble, Belko & Company, Inc
- $634 Million
- Q3 2024
A detailed history of Roble, Belko & Company, Inc transactions in Biogen Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 50 shares of BIIB stock, worth $7,895. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 50
-0.0%
Holding current value
$7,895
Previous $12,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BIIB
# of Institutions
1,036Shares Held
126MCall Options Held
1.13MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.63 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.58 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.3 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.16 Billion0.06% of portfolio
-
Wellington Management Group LLP Boston, MA5.13MShares$810 Million0.18% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $22.7B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...